Isan Chen
Director/Board Member chez TYRA BIOSCIENCES, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Isan Chen is the founder of Mbrace Therapeutics, Inc. (founded in 2020) where he holds the title of President, Chief Executive Officer & Director.
He is currently working as an Independent Director at Tyra Biosciences, Inc. since 2019 and as a Director at Treadwell Therapeutics, Inc. He previously worked as Vice President-Tumor Strategy at Pfizer Inc. from 2004 to 2010, Chief Medical & Development Officer, Executive VP at Mirati Therapeutics, Inc. from 2013 to 2020, and Chief Medical Officer at Aragon Pharmaceuticals, Inc. from 2010 to 2013.
Dr. Chen also held the position of Assistant Professor at The University of Texas M.D.
Anderson Cancer Center.
He obtained a doctorate degree from the University of Sao Paulo.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TYRA BIOSCIENCE, INC
0,37% | 31/05/2023 | 192 783 ( 0,37% ) | 3 M $ | 31/03/2024 |
Postes actifs de Isan Chen
| Sociétés | Poste | Début |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Director/Board Member | 01/02/2019 |
Mbrace Therapeutics, Inc.
 Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | Founder | 01/05/2020 |
Treadwell Therapeutics, Inc.
 Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Director/Board Member | - |
Anciens postes connus de Isan Chen
| Sociétés | Poste | Fin |
|---|---|---|
| MIRATI THERAPEUTICS | Chief Tech/Sci/R&D Officer | 18/05/2020 |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01/07/2013 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2010 |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Formation de Isan Chen
| University of Sao Paulo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| TYRA BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Health Technology |
Mbrace Therapeutics, Inc.
Mbrace Therapeutics, Inc. BiotechnologyHealth Technology Mbrace Therapeutics, Inc. is an American company that specializes in antibody discovery methodology. The company's approach, called SPARTA, overcomes several challenges to generate human antibodies that can be quickly translated into clinical applications. Mbrace Therapeutics was founded by Renata Pasqualini, Isan Chen, and Wadih Arap, with Isan Chen serving as the CEO since incorporation. | Health Technology |
